Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
- PMID: 33762564
- PMCID: PMC8009266
- DOI: 10.12659/MSM.932331
Retracted: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
Abstract
An editorial decision has been made to retract this manuscript due to breach of publishing guidelines, following the identification of non-original and manipulated figures. Reference: Fengli Zhang, Huixiao Chen, Jing Du, Bin Wang, Lixiao Yang: Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Med Sci Monit 2018; 24: 6093-6101. 10.12659/MSM.909745.
Retraction of
-
Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.Med Sci Monit. 2018 Sep 1;24:6093-6101. doi: 10.12659/MSM.909745. Med Sci Monit. 2018. Retraction in: Med Sci Monit. 2021 Mar 25;27:e932331. doi: 10.12659/MSM.932331. PMID: 30171812 Free PMC article. Retracted.
Similar articles
-
Retracted: Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT Signalling Pathway.Med Sci Monit. 2021 Mar 25;27:e932342. doi: 10.12659/MSM.932342. Med Sci Monit. 2021. PMID: 33762568 Free PMC article.
-
Retracted: Anticancer Activity of Mukonal Against Human Laryngeal Cancer Cells Involves Apoptosis, Cell Cycle Arrest, and Inhibition of PI3K/AKT and MEK/ERK Signalling Pathways.Med Sci Monit. 2022 Jul 19;28:e937840. doi: 10.12659/MSM.937840. Med Sci Monit. 2022. PMID: 35850997 Free PMC article.
-
Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.Med Sci Monit. 2018 Sep 1;24:6093-6101. doi: 10.12659/MSM.909745. Med Sci Monit. 2018. Retraction in: Med Sci Monit. 2021 Mar 25;27:e932331. doi: 10.12659/MSM.932331. PMID: 30171812 Free PMC article. Retracted.
-
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.Crit Rev Oncol Hematol. 2016 Sep;105:73-83. doi: 10.1016/j.critrevonc.2016.06.006. Epub 2016 Jun 18. Crit Rev Oncol Hematol. 2016. PMID: 27378194 Review.
-
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.Semin Cancer Biol. 2019 Dec;59:147-160. doi: 10.1016/j.semcancer.2019.05.012. Epub 2019 May 22. Semin Cancer Biol. 2019. PMID: 31128298 Review.
References
-
- Zhang Fengli, Chen Huixiao, Du Jing, Wang Bin, Yang Lixiao. Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Med Sci Monit. 2018;24:6093–6101. doi: 10.12659/MSM.909745. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous